Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China.
Laboratory of Clinical Microbiology, West China Hospital, Sichuan University, Chengdu, China.
J Glob Antimicrob Resist. 2020 Dec;23:404-407. doi: 10.1016/j.jgar.2020.10.023. Epub 2020 Nov 17.
The aim of this study was to investigate the clinical characteristics and outcomes of patients with infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) treated with ceftazidime/avibactam (CAZ/AVI) during the period September 2019 to June 2020 since CAZ/AVI had been marketed in China.
A total of 20 MDR-GNB-infected patients were retrospectively identified using the electronic medical record system in West China Hospital.
The mean age of the 20 patients was 54.5 ± 17.37 years and 14 (70%) were male. Pneumonia (n = 12; 60%), complicated intra-abdominal infection (n = 10; 50%), and bloodstream infection (n = 7; 35%) were the most common infection sources. Klebsiella pneumoniae (55% 18/33) was the predominant pathogen. The 14-day clinical cure rate was 45%. The 14-day and 30-day mortality rates were 25% and 55%, respectively. No significant difference was found in 30-day mortality between treatment with CAZ/AVI monotherapy and combination regimens (P > 0.05). Three patients suffered from adverse drug reactions such as diarrhoea.
No significant difference was found between the effectiveness of CAZ/AVI in the clinical failure and cure groups as salvage treatment of MDR-GNB infection.
本研究旨在调查 2019 年 9 月至 2020 年 6 月 CAZ/AVI 在中国上市以来，使用头孢他啶/阿维巴坦（CAZ/AVI）治疗多重耐药革兰阴性菌（MDR-GNB）感染患者的临床特征和结局。
通过电子病历系统回顾性确定了华西医院 20 例 MDR-GNB 感染患者。
20 例患者的平均年龄为 54.5±17.37 岁，14 例（70%）为男性。肺炎（n=12；60%）、复杂腹腔内感染（n=10；50%）和血流感染（n=7；35%）是最常见的感染源。肺炎克雷伯菌（55%，18/33）是主要病原体。14 天临床治愈率为 45%。14 天和 30 天死亡率分别为 25%和 55%。CAZ/AVI 单药治疗与联合治疗方案在 30 天死亡率方面无显著差异（P＞0.05）。3 例患者出现腹泻等药物不良反应。
CAZ/AVI 作为 MDR-GNB 感染的挽救治疗，在临床失败和治愈组的疗效之间无显著差异。
